AI Summary
✦ ClarthaValuation Metrics
Trading 29.8% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -1.45). Confidence: 81%.
Live forward EPS implies next-12-month EPS of ₹5.29. Applying the stock's normalized valuation corridor produces a fair range of ₹56.50 to ₹77.92, with base value near ₹70.36 (+6.7% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹5.29
Forward P/E
12.5x
Base Fair Value
₹70.36
Fair Range
₹56.50 - ₹77.92
Upside To Base
+6.7%
Estimate Source
Live forward EPS
5Y Average
11.31
Current
9.34
Overvalued
14.73
Undervalued
10.68
5Y Average
92.60
Current
76.47
Overvalued
112.02
Undervalued
73.69
5Y Average
1.59
Current
1.31
Overvalued
1.83
Undervalued
1.35
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.3x Undervalued | -24% vs avg | +9.3% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +22.0% | 15.8% | 25.8x Undervalued | -41% vs avg | +20.5% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 48.9x Fair | +11% vs avg | -1.7% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 90.3x Premium | +105% vs avg | +116.1% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.1x Undervalued | -18% vs avg | +11.3% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.5x Fair | -13% vs avg | -15.8% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 40.2x Fair | -9% vs avg | +28.0% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.8x Fair | -10% vs avg | +30.6% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Financial chart data is not available for this company right now.
Results
Income statement data not available.
All values in ₹ Crores unless otherwise stated. Source: Company filings.